AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2024

'Rs in millions except for earnings per share data

Sl No.	Particulars	3 months ended 30/06/2024	Previous 3 months ended 31/03/2024	Corresponding 3 months ended in the previous year 30/06/2023	Year ended 31/03/2024
		Unaudited	Refer Note 4	Unaudited	Audited
1	**Income**				
	a) Revenue from operations	3,875.2	3,832.0	2,954.7	12,955.3
	b) Other income	83.5	86.6	81.0	348.0
	Total income	**3,958.7**	**3,918.6**	**3,035.7**	**13,303.3**
2	**Expenses**				
	(a) Cost of materials consumed	458.5	336.2	190.8	1,290.2
	(b) Purchase of stock-in-trade	2,403.3	749.8	1,028.5	4,993.1
	(c) Changes in inventories of finished goods, work-in-progress and stock in trade	(557.4)	1,049.5	(113.4)	(337.7)
	(d) Employee benefit expense	609.6	579.8	549.7	2,414.5
	(e) Depreciation expense	39.1	37.6	37.9	149.4
	(f) Allowance for expected credit loss (net)	(10.2)	41.8	(2.2)	54.4
	(g) Selling, marketing and distribution expense	183.7	211.4	212.7	860.1
	(h) Other expenses	407.0	369.6	416.2	1,836.2
	(i) Finance costs	1.1	(0.7)	1.5	12.0
	Total expenses	**3,534.7**	**3,375.0**	**2,321.7**	**11,272.2**
3	**Profit before exceptional items and tax (1-2)**	**424.0**	**543.6**	**714.0**	**2,031.1**
4	Exceptional items (expense) / income (Refer Note 3)	(575.6)	-	-	164.3
5	**Profit / (loss) before tax (3+4)**	**(151.6)**	**543.6**	**714.0**	**2,195.4**
6	**Tax expense**				
	(a) Current tax	103.1	155.2	174.7	535.5
	(b) Tax expense for prior years	4.4	-	-	53.8
	(c) Deferred tax charge / (credit)	(141.2)	(6.4)	0.7	(9.0)
	Total tax expense	**(33.7)**	**148.8**	**175.4**	**580.3**
7	**Profit / (loss) after tax (5-6)**	**(117.9)**	**394.8**	**538.6**	**1,615.1**
8	**Other comprehensive income**				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurement gains / (losses) on post employment benefit obligations	9.9	2.7	6.1	13.3
	(b) Income tax effect on above	(2.5)	(0.7)	(1.5)	(3.3)
	Other comprehensive income, net of income tax	**7.4**	**2.0**	**4.6**	**10.0**
9	**Total comprehensive income / (loss) for the period (7+8)**	**(110.5)**	**396.8**	**543.2**	**1,625.1**
10	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**50.0**	**50.0**	**50.0**	**50.0**
11	**Other equity**	-	-	-	7,069.2
12	**Earnings per equity share of Rs 2/- each (basic and diluted)**	**(4.72)**	**15.79**	**21.54**	**64.60**

AstraZeneca Pharma India Limited Bangalore

Price Waterhouse & Co Chartered Accountants LLP LLPIN AAC-4362 FRN 304026E/E-300009 Bengaluru

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2024

Notes:

1 The Statements of unaudited financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.

3 **Exceptional items**

a In continuation with the Company's earlier announcement of intent to exit its manufacturing site on 16 November 2023, the Company explored the option of sale of the manufacturing site in a fully operational manner to a Contract Manufacturing Organisation. The Company was unable to find a suitable one and has made an announcement to Stock exchanges on 21 June 2024 that it will now explore a buyer for its manufacturing site and exit in due course. The exit is estimated to take more than 12 months. Consequently, the company has accounted for provisions related to closure of its manufacturing site amounting to Rs.575.6 Million as exceptional item in the quarter ended 30 June 2024 as per the relevant Indian Accounting Standards.

b The Company had entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs.164.3 Million is disclosed as an exceptional income for the year ended 31 March 2024.

4 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year 31 March 2024 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e., 31 December 2023 which were subjected to limited review by the statutory auditors.

5 The Company has decided to change the rounding off principle followed in the Statement of financial results from lakhs of rupees to millions of rupees from the current quarter.

6 This Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 8 August 2024. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2024.

AstraZeneca Pharma India Limited Bangalore

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 8 August 2024

Price Waterhouse & Co Chartered Accountants LLP LLPIN AAC-4362 FRN 304026E/E-300009 Bengaluru